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 ABSTRACT 
The therapeutic promise of small interfering RNAs (siRNAs) for specific gene
silencing is dependent on the successful delivery of functional siRNAs to the
cytoplasm. Their conjugation to an established delivery platform, such as gold
nanoparticles, offers tremendous potential for treating diseases and advancing
our understanding of cellular processes. Their success or failure is dependent on
both the uptake of the nanoparticles into the cells and subsequent intracellular
release of the functional siRNA. In this study, utilizing gold nanoparticle 
siRNA-mediated delivery against C-MYC, we aimed to determine if we could 
achieve knockdown in a cancer cell line with low levels of intracellular glutathione,
and determine the influence, if any, of polyethylene glycol (PEG) ligand density 
on knockdown, with a view to determining the optimal nanoparticle design to
achieve C-MYC knockdown. We demonstrate that, regardless of the PEG density,
knockdown in cells with relatively low glutathione levels can be achieved, as well
as the possible effect of steric hindrance of PEG on the availability of the siRNA
for cleavage in the intracellular environment. Gold nanoparticle uptake was
demonstrated via transmission electron microscopy and mass spectroscopy,
while knockdown was determined at the protein and physiological levels (cells 
in S-phase) by in-cell westerns and BrdU incorporation, respectively.  
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1 Introduction 
With recent advances in gene discovery and analysis, 
the relationship between gene dysfunction and disease 
phenotype is being unraveled. Gene therapy has 
therefore become an attractive area of research, by 
targeting diseases at the genetic level. Small interfering 
RNAs (siRNAs) are double-stranded RNAs appro-
ximately 20–25 nucleotides long that are involved in 
the RNA interference pathway. siRNAs bind specifically, 
with complete complementarity, to their target RNA 
sequences, halting their expression; thus, they offer 
an attractive mechanism for successful and specific 
gene therapy [1]. A report by Derfus et al. indicated 
that one siRNA molecule per particle conjugated 
with >15 peptides produced optimal knockdown and 
targeting [2]. 
However, the clinical translation of gene therapy 
has been set back due to technical issues surrounding 
the delivery of genetic material. When considering 
siRNA delivery, the main steps towards successful 
delivery include: (1) cellular localization and binding, 
(2) cellular internalization, (3) subcellular trafficking 
and endosomal escape, and (4) release of functional 
siRNA capable of interaction with the RISC complex 
(containing cellular machinery for silencing to progress) 
[3]. Therefore, there is a pressing need to design a 
delivery platform capable of protecting siRNA from 
degradation and safely delivering it to target cells 
while maintaining its functionality. 
To this end, nanoparticles have been hailed as a 
revolutionary vehicle for targeted cellular delivery. 
Gold nanoparticles (AuNPs) in particular have become 
popular in biomedicine; aside from their unique 
physical and chemical properties, they are biologically 
inert and have a history of biomedical use that spans 
decades [4]. AuNPs have the additional advantage of 
being easily synthesized, with excellent control over 
size, shape, stability, and surface modification [4]. 
The choice of ligands on the nanoparticle surface and 
their molecular size and organization will influence 
their biological properties, and careful design is 
required. 
Polyethylene glycol (PEG) is often utilized to passivate 
AuNPs for biological use, owing to its inherent protein 
repulsion tendency. The steric tethering of PEG chains 
to AuNPs confers ideal stability under physiological 
conditions, while minimizing interaction with 
biomacromolecules, which might otherwise lead to 
aggregation. This protein repulsion tendency of PEG 
does not depend on the nature of PEG binding to the 
NP, as both covalently and electrostatically bound 
PEG show good protein rejection capacity; however, 
stronger binding can ensure that PEG functionality is 
not lost [5]. To date, when utilizing PEG, researchers 
have focused on the importance of the PEG chain 
length, as it has been established that shorter chains 
provide enhanced cellular uptake [6]. There are mixed 
reports with respect to PEG chain density on the surface 
of an NP, mainly due to both the branching effect and 
overall molecular weight. Hypothetically, a higher 
molecular weight may provide better flexibility (through 
long chain molecules), but this will also make the NP 
larger and restrict attachment of additional ligands. It 
is therefore generally thought that a high density of 
short-chain PEGs is preferred for achieving optimum 
cellular uptake while maintaining the PEGylated 
particle’s stealth properties [5]. 
A final, and critical, consideration in the AuNP 
design is the intracellular release of functional siRNA 
from the AuNP surface. Here, the strong thiol-Au 
interaction is readily exploited to allow exchange 
between –S/Au- and thiol-containing molecules such 
as glutathione in the cytoplasm, leading to efficient 
dissociation from the gold surface [7]. Glutathione 
(GSH) is an abundant thiol-containing compound in 
most cells, and is found in the millimolar range in the 
cytoplasm of healthy cells, making it an excellent 
candidate for GSH-triggered siRNA release [8]. 
Functionalized AuNPs are therefore highly promising 
vehicles for gene therapy, as they can be synthesized 
with a view to protecting the genetic material from 
degradation and demonstrate efficient uptake, while 
also being designed to target specific cell types [9–11]. 
In previous work, we have demonstrated that AuNPs 
with a low concentration of PEG functionalized with 
thiolated siRNA were capable of inducing C-MYC 
knockdown in HeLa cells [12]. In the present study, 
with regards to AuNP functionality, our aims were 
twofold: (i) to determine if we could achieve C-MYC 
knockdown in a cancerous cell line that contains a 
lower intracellular GSH concentration than HeLa cells, 
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and (ii) to determine the importance of the degree of 
saturation of the PEG layer in terms of siRNA release 
within the cells. To this end, the bone carcinoma  
cell line MG63 [12] was employed in this study, and 
challenged with AuNPs with two PEG densities: 25% 
and 40%. The results demonstrate that, while MG63s 
exhibited relatively lower GSH levels compared to 
other cancer cell lines, C-MYC knockdown was still 
achieved. Interestingly, a variation in efficacy was 
noted that favored the lower 25% PEG density. At the 
higher concentration of 15 nM, the 25% PEG-containing 
AuNPs induced a significantly better knockdown in 
C-MYC protein, with similar trends in cell proliferation 
levels. Conversely, at the lower concentration of 2 nM, 
while protein knockdown was comparable, a signi-
ficantly greater reduction in cell proliferation was 
noted with 25% PEG. Following the comparison of 
intracellular GSH levels in MG63 cells, and two other 
established cancer cell lines (MCF-7 and HeLa), it was 
surmised that perhaps the considerably lower GSH 
levels found in MG63 cells render the cells less able 
to access the siRNA at the higher PEG density of 40%. 
This observation suggests that the required GSH-thiol 
interaction that is needed for siRNA release within 
the cell is finely balanced, and must be addressed when 
designing NPs for therapeutic use.  
2 Materials and methods 
2.1 Synthesis and functionalization of gold  
nanoparticles 
AuNPs with a diameter of 14 nm were synthesized by 
the citrate reduction method described by Turkevich 
and Frens in Refs. [13–15]. A mixture of AuNPs, 
0.028% SDS, and HS-EG(8)-(CH2)2-COOH (Iris-Biotech) 
(MW = 458 Da) and HS-(CH2)3-CONH-EG(6)-(CH2)2-N3 
(synthesized in our lab) (MW = 452 Da)
 
in a 1:1 ratio  
(7 and 10.5 μM of each chain for 25% and 40%, 
respectively) was combined under basic conditions 
for 16 h. PEGylated AuNPs (~8 PEG unit lengths) 
were obtained after purification by centrifugation. 
Quantification of the number of PEG molecules attached 
was performed by Ellman’s method by calculating the 
excess thiolated PEG chains found in the supernatant. 
For fine tuning the PEG density, different amounts  
of PEG-COOH were used in the experiment (the 
presence of PEG-N3 had already been demonstrated 
by our group in Ref. [12]). The AuNPs obtained were 
characterized by UV-Vis spectroscopy, transmission 
electron microscopy (TEM), zeta potential, and dynamic 
light scattering (DLS). 
Further chemical functionalization with biotin 
(labeled as B) was performed using 1-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide (EDC) (Sigma- 
Aldrich) and sulfo-hydroxysuccinimide (sulfo-NHS) 
(Sigma-Aldrich) chemistry at pH 6.1 (25 mM MES). 
AuNP was functionalized with siRNA (Thermo 
Scientific Dharmacon) (labeled as S) using thiolated 
siRNA previously reduced with dithiothreitol (DTT) 
incubated with AuNPs followed by the addition of 
0.028% SDS and NaCl at a final concentration of 0.1 M 
(25% saturated AuNPs) or 0.3 M (40% saturated 
AuNPs). Excess siRNA was removed by centrifugation 
at 4 °C. siRNA was quantified by fluorescence mea-
surement of supernatants (Perkin-Elmer LS55) using 
GelRed (Biotium), a nucleic acid intercalator, after 
establishing a calibration curve with the thiolated 
siRNA used (Emission at 602 nm = 7,328.3 × [siRNA, 
n mol] + 39.366). The panel of four AuNPs and PEG 
chain densities employed in this study are described in 
the legend (with associated acronyms) in Table 1, with 
a schematic illustrating the ligands attached to the 25% 
and 40% PEG saturated AuNPs shown in Fig. 1.  
Table 1 A complete list of the AuNPs used in this study and the 
corresponding PEG ligand densities. Please note that B denotes 
biotin and S denotes siRNA 
 Nanoparticle type PEG ligand density (chains per nm2) 
1 Au-B-25% PEG ~ 2.03 
2 Au-B-S-25% PEG ~ 2.03 
3 Au-B-40% PEG ~ 2.99 
4 Au-B-S-40% PEG ~ 2.99 
2.2 Cell culture 
The human osteosarcoma cell line MG63 was cultured 
in DMEM growth medium (10% fetal bovine serum, 
2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL 
streptomycin) and maintained at 37 °C in 5% CO2 
until ~90% confluent, after which they were passaged  
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Figure 1 Schematic of the 25% and 40% PEG saturated AuNPs 
with associated ligands. 
and counted with a hemocytometer. Cells were seeded 
at a density of 1 × 104 cells per mL for experiments 
unless stated otherwise. Cells were cultured for 24 h 
before the addition of both the 25% and 40% PEG 
AuNP treatments at 2 and 15 nM.  
2.3 GSH assay 
The MG63 cells employed in this study and two 
other established cancer cell lines, HeLa and MCF-7, 
were cultured and harvested (1 × 106 cells were collected 
for each cell line) to determine cytoplasmic GSH 
levels. The cells were lysed with lysis buffer (GSH kit 
obtained from AbCam), incubated on ice for 10 min, 
and centrifuged at 13,000g for 10 min. A standard 
GSH curve was prepared alongside the samples. 
Monochlorobimane [16], a dye that forms an adduct 
with GSH, was added to the well and the plate   
was incubated for 1 h at 37 °C. The fluorescence was 
measured using a plate reader with EX/EM = 360/ 
420 nm. 
2.4 Toxicity 
Cytotoxicity was assessed by a standard MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay. Cells were seeded in a 96-well plate in triplicate. 
Following incubation with the AuNPs, cells were 
incubated in 100 L of MTT solution (Sigma- Aldrich; 
5 mg/mL in phosphate-buffered saline (PBS)) for 60 min 
at 37 °C, after which the MTT was aspirated off and 
100 L of dimethyl sulfoxide (Thermo Fisher Scientific, 
Waltham, MA) was added for 10 minutes. The plate was 
subsequently read via spectrophotometry (Dynatech 
MR7000 at 550 nm). 
2.5 Cellular uptake of AuNPs 
2.5.1 Inductively coupled plasma mass spectrometry 
(ICP-MS) 
Cells were seeded (100 L/well) in a 96-well plate and 
incubated for 24 h, followed by the addition of 
AuNPs and an additional 48-h incubation. The media 
were transferred to 1 mL H2O (Millipore Ultra-Pure), 
followed by the addition of 1 mL of 70% HNO3 and 
incubation overnight in a 70 °C water bath. Samples 
were adjusted to 50 mL with Millipore Ultra-Pure 
water and analyzed by ICP-MS at the University of 
West Scotland (Paisley, UK). The converted values  
for gold uptake were averaged (n = 3) and used for 
statistical analysis. 
2.5.2 TEM 
Cells were seeded at a density of 4 × 104 cells per mL 
onto Thermanox coverslips (13 mm in diameter) and 
cultured to develop a confluent monolayer of cells. 
At this point, the AuNPs were added and cells were 
cultured for another 24 h. Cells were subsequently 
fixed with 1.5% glutaraldehyde in phosphate buffer 
(1.15 g/L Na2HPO4, 0.2 g/L KH2PO4, 8 g/L NaCl and 
0.2 g/L KCl) for 2 h, and washed for 10 min with PBS. 
Cells were then post-stained for 60 min with 1% 
osmium tetroxide in phosphate buffer, post-fixed in 
1% buffer followed by 0.5% uranyl acetate for 1 h, 
and then dehydrated in increasing concentrations of 
alcohol and left in resin (propylene oxide Epon 812 
resin mix (1:1)) overnight. Cell layers were captured 
in pure resin and cured overnight in an oven. Blocks 
were then cut into ultrathin sections, stained with 2% 
methanolic uranyl acetate and Reynolds lead citrate, 
and viewed under a Leo 912 AB TEM (120 kV for cells).  
2.6 C-MYC knockdown 
2.6.1 In-cell western (ICW) 
Cells were seeded in a 96-well plate in triplicate, 
challenged with the AuNPs for 24 and 48 h, then fixed, 
permeabilized, and blocked as in section 2.5. Samples 
were then co-incubated with primary antibodies 
(1:10,000 mouse anti-C-MYC, [9E10], ChIP Grade (ab32), 
AbCam and 1:10,000 rabbit anti-GAPDH, Epitomics)  
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at 37 °C for 1 h. Following washing with PBS/Tween, 
samples were co-incubated with secondary antibodies 
(1:10,000 donkey anti-mouse IR680RD, LI-COR 
Biosciences, Cambridge, UK and 1:10,000 donkey 
anti-rabbit IR800CW, LI-COR Biosciences) at 37 °C for 
1 h. All samples were finally washed three times in 
PBS/Tween (5 min per wash). The plates were imaged 
by scanning simultaneously at 700 and 800 nm with an 
Odyssey SA at 100 μm resolution, medium quality, 
focus offset of 3.53 mm, and an intensity setting of 7 
for both 700- and 800-nm channels. 
2.6.2 BrdU proliferation assay 
Cells were seeded onto 13-mm glass coverslips for 
24 h, and further incubated with AuNPs for 42 h. 
After this time, 1 mM BrdU (Sigma-Aldrich) solution 
was added and the cells cultured an additional 6 h. 
The media were removed and cells were washed in 
PBS, fixed, permeabilized, and blocked as in section 
2.5. Anti-BrdU antibody (Cell Proliferation Kit RPN20, 
GE Healthcare, Buckinghamshire, UK) was diluted 
1:100 in DNase I and added and the cells were 
incubated for 2.5 h at 37 °C. Cells were then washed 
3 times before incubating with Texas Red-conjugated 
anti-mouse antibody (1:50 in PBS/1% bovine serum 
albumin) for 1 h. Cells were finally mounted and 
stained with DAPI (Vector Laboratories). Cells   
were imaged using an Axiovert 200m fluorescence 
microscope (Carl Zeiss, Jena, Germany) equipped with 
ImagePro Plus Version 6.01 software (Media Cybernetics) 
and a sideport-mounted Evolution QEi Monochrome 
CCD camera (Media Cybernetics). 
2.7 Statistics 
Statistical analysis was performed in GraphPad using 
one-way ANOVA and Dunnett’s post-test. In all figures 
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** = p < 
0.0001. Two-tailed t-tests were performed where 
specifically mentioned using Welch’s correction: = p < 
0.05, = p < 0.01 
3 Results 
3.1 Synthesis and functionalization of AuNPs 
AuNPs were synthesized using Turkevich and Fren’s 
method and subsequently functionalized with different 
amounts of thiolated PEG chains in order to achieve 
different densities of the PEG layer surrounding the 
AuNP core. The quantification of the attached PEG 
chains was made by quantification of the free thiol 
groups present on the supernatants after purification 
by Ellman’s assay. A complete study was performed 
using PEG-COOH to generate a corresponding 
saturation curve of the surface of the AuNP (Fig. 2(a)). 
The presence of the PEG-N3 had already been tested 
for different amounts of PEG in previous work by 
our group in Ref. [12]. These AuNPs (Au 25% PEG 
and Au 40% PEG) were further characterized by TEM, 
DLS, and zeta potential (Figs. 2(b1)–2(b3)). 
The terminal carboxylic groups of PEG chains were 
subsequently functionalized with aminated biotin 
through a carbodiimide-induced coupling reaction. 
Finally, thiolated siRNA was directly bound to the 
AuNP core in the presence of SDS and subsequent 
additions of salt up to 0.1 M for Au-B 25% PEG and 
to 0.3 M for Au-B 40% PEG. While the same amounts 
of thiolated siRNA were used for both the 25% and 
40% PEG AuNPs, it should be noted that a slightly 
higher level of siRNA ligands might attach to the 25% 
sample (due to the different salt concentrations used 
in synthesis). The amount of thiolated siRNA attached 
was calculated by measuring the excess siRNA in the 
supernatants after adding GelRed. The stability of  
all samples was monitored at each step by UV–Vis 
spectroscopy (Fig. 2(c)). 
3.2 Intracellular GSH levels 
The NPs were designed based on the established 
AuNP/GSH interaction within the cytoplasm, whereby 
GSH cleaves thiol bonds that in turn release the 
thiolated siRNA from the gold core. The levels of GSH 
in the current cell line, MG63, were determined and 
compared to GSH levels in both HeLa and MCF-7 
cancer cell lines (Fig. 3 and Table S1 in the Electronic 
Supplementary Material (ESM)). MG63 cells were 
found to have relatively low GSH levels in comparison 
to both MCF-7 and HeLa cells, with that of HeLa cells 
being approximately 4 times higher (Fig. 3). From 
previous studies, we established that C-MYC knock-
down in HeLa cells using thiol exchange via GSH 
was easily achievable; therefore, MG63 were selected  
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Figure 3 Glutathione (GSH) levels present in MG63 cells, MCF-7, 
and HeLa cancer cell lines. Cell number was normalized to 1 × 106 
cells and values were plotted onto a GSH standard curve (n = 3). 
Crosses indicate GSH standards, while the squares correspond to 
the cell type. Dashed areas around cell type indicate SD. 
to test the level of functionality achievable with our 
siRNA-AuNPs in a cancer cell line of known lower 
GSH concentration. 
3.3 Toxicity: MTT assay 
The AuNPs were found to have no cytotoxicity over 
24 h of incubation, as demonstrated by the MTT assay, 
showing no statistical difference between treatments 
(Fig. 4).  
3.4 Cellular uptake of AuNPs  
To examine AuNP uptake in greater detail, TEM with 
cross-sectional imaging was used. At the lower 25% 
PEG saturation, the AuNPs were all distinctly located 
in the cytoplasm, and perhaps more apparent at the 
higher 15 nM concentration (Fig. 5). Images for the 
40% PEG saturation were similar, again with AuNPs 
evident in the cell body (Fig. 6). The NPs were evident 
within the cell after 24 h of incubation. 
In parallel with qualifying AuNP uptake into  
cells, the amount of AuNPs within the cells was  
also quantified after 24 h using ICP-MS to determine 
elemental gold levels in lysed cell samples. All AuNP 
types were recorded in the cells (Fig. 7). Clear evidence 
was shown that more AuNPs were present at the 
higher concentration, confirming the validity of the 
method. Between the AuNP species at both concen-
trations, there was no significant difference between 
the 25% and 40% PEG with regards to uptake (unpaired 
t-test with Welch’s correction). 
 
Figure 2 Study of the saturation of the AuNP’s surface with PEG chains (a), characterization of the 25% PEG saturated (b1) and 40% 
PEG saturated (b2) AuNPs by TEM, and by zeta potential and DLS (b3); UV–Vis spectrum of all the AuNPs used in this study (c). 
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Figure 5 TEM images of MG63s treated with 15 and 2 nM 
AuNPs, with 25% PEG after a 24-h incubation. Clusters of the 
AuNPs are evident within the cell body. Scale bar = 1 µm. 
3.5 siRNA-mediated C-MYC knockdown 
Following verification and quantification of AuNP 
uptake into MG63 cells, the efficiency of siRNA- 
mediated C-MYC silencing was evaluated using ICW. 
The higher concentration (15 nM) produced knockdown 
 
Figure 6 TEM images of MG63s treated with 15 and 2 nM 
AuNPs, with 40% PEG after a 24-h incubation. As with the 25% 
PEG-containing AuNPs, clusters of AuNPs are evident within the 
cell body. 
at both PEG densities (25% and 40%); however, the 
25% density was significantly more effective. The 
lower concentration (2 nM) produced comparable 
knockdown, with no difference noted between the 
densities. The optimal knockdown was achieved with 
 
Figure 4 MTT analysis of MG63 cells treated with 15 and 2 nM of each AuNP, with 40% or 25% PEG coverage for 24 h (B = biotin;
S = siRNA). Samples were normalized to MG63s without AuNPs (n = 3; error bars indicate SD). 
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a combination of both approaches, using the higher 
concentration (15 nM) and lower PEG density (25%) 
(Fig. 8). There was also a significant reduction in C-MYC 
protein noted for one of the controls, Allstar nonsense 
siRNA with Lipofectamine; however, this result may 
be due to the Lipofectamine affecting cell proliferation. 
The synthetic nucleoside BrdU was used to analyze 
cells entering S-phase in the cell cycle, thus giving an 
indication of cell division in the sample population. 
As shown in Fig. 9, there was a higher proportion of 
cells in S-phase (red) in the standard control cells (with 
no AuNPs) and cells treated with the additional 
control NPs (biotin and PEG only), in contrast to the 
lack of any cell division detected in cells treated with 
the siRNA AuNPs (Fig. 9). To quantify this property, 
ten random images were obtained from each cell 
sample (n = 3 per sample) and the proportion of cells 
in S-phase was determined using Cell Profiler (Fig. 10). 
The results demonstrate a significant decrease in cells 
entering S-phase when treated with siRNA at the  
 
Figure 7 ICP-MS analysis of MG63s treated with 2 and 15 nM of AuNPs, with 25% or 40% PEG coverage for 24 h (n = 3 for each lysate,
error bars denote SD). The higher concentration (15 nM) clearly led to higher gold levels in cells. All values have been normalized to
that of ultrapure water. 
 
Figure 8 ICW data comparing C-MYC protein levels in MG63s with AuNP treatments, normalized to that of GAPDH. Cells were
serum starved for 24 h before treatment to synchronize cell division. NPs were added at both 2 and 15 nM, with both 25% and 40% PEG 
coverage. The standard control reflects cells without AuNPs added. Additional controls included Lipofectamine alone, C-MYC siRNA 
with Lipofectamine (CL), Allstar nonsense siRNA with Lipofectamine (AL), or C-MYC siRNA or Allstar siRNA added directly to the 
media (CN & AN) (n = 6; error bars denote standard error, asterisk denotes significance based on ANOVA, with Dunnett’s post-test for 
normalizing to controls. Hash marks indicate an unpaired two-tailed t-test with Welch’s correction p < 0.005). 
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Figure 9 BrdU incorporation into cells treated with 2 and 15 nM 
AuNPs, with either 25% or 40% PEG coverage for 48 h. Cells were 
stained for nuclei (DAPI: blue) and actively dividing cells (BrdU: 
red). Additional controls included Lipofectamine alone, CL, AL, 
or CN & AN. Scale bar = 20 µm. 
higher concentration (15 nM) at both PEG densities 
(25% and 40%), but cell proliferation was only decreased 
at the lower PEG density (25%) when tested at 2 nM. 
4 Discussion 
The use of intracellular GSH as a release mechanism 
has been capitalized upon with a view towards thio- 
tethered ligand release from the surface of NPs [17–24]. 
While there have been several recent studies on the 
influence of the PEG chain length and ligand release [6], 
mixed reports on the effect of PEG density prompted 
this study, with a shorter chain length and higher 
density having been considered optimum for both 
ligand release and maintenance of the PEGylated 
particles’ stealth properties [5].  
Previous work involving our group has shown that 
PEGylated AuNPs functionalized with siRNA against 
C-MYC can knock down its expression in HeLa cells 
(2 nM with a PEG ligand density of 25%) [12]. The 
present study was designed to assess both the potency 
of the AuNPs, by assessing the knockdown in a cancer 
cell line with a lower intracellular GSH level, and the 
influence of PEG chain density on C-MYC knockdown. 
The NPs were PEGylated at both 25% and 40%, and 
were used at two concentrations, 2 and 15 nM. Follo-
wing cellular toxicity and AuNP uptake assessment, 
C-MYC knockdown was determined. 
When investigating C-MYC knockdown at the protein 
level, the higher concentration (15 nM) achieved clear 
knockdown at both 25% and 40% PEG density, with 
the lower 25% density achieving a significantly more 
pronounced knockdown (left-side values on the graph  
 
Figure 10 Graphical representation of the BrdU images as determined by Cell Profiler, normalized to nuclei number, comparing the 
level of MG63 cells in S-phase with different treatments (results from 10 images, n = 3 replicates, error bars denote standard error, asterisk
denotes significance based on ANOVA with Dunnett’s post-test to normalize to controls. Hash marks indicate unpaired two-tailed t-test 
with Welch’s correction p < 0.05). 
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in Fig. 8). Meanwhile, the lower concentration (2 nM) 
also achieved knockdown at both densities, but to a 
lesser extent. At the physiological level, when deter-
mining changes in cell proliferation, the previously 
observed difference in protein knockdown evident at 
15 nM was not apparent, with a comparable reduction 
in proliferation noted for both densities. However, 
for the lower concentration (2 nM), which produced a 
comparable protein knockdown, only the 25% PEG 
density resulted in a reduction in proliferation. 
Therefore, while the 25% PEG AuNPs have slightly 
higher levels of siRNA ligand attached, which may 
amplify this effect, these results still indicate that    
a variation in knockdown may be observed when 
adopting different PEG saturation densities, which may 
have consequences with regards to the therapeutic 
potential of siRNA.   
GSH is an abundant thiol-cleaving enzyme located 
within cells. During normal cellular processes GSH 
exists in two distinct forms: oxidized (GSSH) and 
reduced (GSH). The oxidized form is <2% of total 
GSH levels [25]. GSH is used in many processes within 
the cells such as detoxification, removal of hydro-
peroxides, and maintaining oxidation of protein 
sulfhydryls [26–28]. Healthy cells tend to have GSH 
levels within the 1–10 mM range, an order of magnitude 
higher than in the extracellular environment [29]. 
Our AuNPs were designed with a view towards 
exploiting GSH’s ability to cleave the thiol-conjugated 
siRNA. Increasing PEG length and ligand density to 
saturation can complicate access to the thiol [6], with 
greater ligand density or higher molecular weight 
polymers preventing access to the core [30]. Once 
released, the double-stranded siRNA is loaded into 
the RISC complex. Within the RISC complex, Ago2 
cleaves the sense strand and dissociates it from the 
complex, after which it will ultimately be degraded 
[31]. The antisense strand, which is complementary 
to the target mRNA, will remain bound to the RISC 
complex until it recognizes the target sequence. Ago2 
mediates the cleavage of the target mRNA ~10–11 
nucleotides upstream of the guide strand’s 5’ end. 
After degradation, the components of the RISC complex 
are recycled [32]. 
While ligand-based NPs are championed as holding 
great potential in future cancer diagnosis and therapy, 
they have thus far delivered inconsistent results. One 
of the major factors contributing to this inconsistency, 
along with other ligand issues, is thought to be 
differences in passivating PEG coatings on the NPs 
[6]. As discussed in the introduction, the PEG chain 
length is known to influence the NP-cell interactions; 
however, it is also well established that the PEG density 
on an NP surface can also affect the protein repelling 
capacity of the resultant NPs, and therefore influence 
the particles’ stealth properties [33, 34]. The PEG density 
has also been identified as being key in determining 
cell uptake [6]. In the present study, the AuNPs with 
40% PEG coverage demonstrated marginally lower 
uptake levels compared to the 25% PEG AuNPs (as 
demonstrated by ICP-MS results), and the TEM images 
indicated clear availability of the 40% PEG AuNPs  
in the cytoplasm. Thus, the 40% PEG density did not 
appear to hinder cellular uptake.  
It is well established that ligand surface coverage, 
density, and conformation of functionalized NPs is of 
critical importance to the success of NP delivery 
systems; however, studies on these parameters have 
been lacking. Until only very recently, data on ligand 
densities on AuNPs (in the 10–100 nm range) were 
seldom reported [35]. This apparent paucity of data 
may be due in part to technical difficulties in obtaining 
such data, with X-ray crystallography and density 
functional theory studies being performed to derive 
theoretical considerations [36]. In this study, we surmise 
that the lower coverage of PEG potentially allowed 
greater access of the siRNA to the intracellular 
environment and the RISC complex, which was 
reflected in (i) the significantly reduced C-MYC protein 
levels recorded with 25% PEG at 15 nM (Fig. 8), and 
(ii) the reduction in cell proliferation observed with 
25% PEG at 2 nM, while 40% PEG was similar to 
control levels (Fig. 10). The most pronounced C-MYC 
knockdown occurred using 15 nM and 25% PEG in 
tandem, which resulted in more efficient knockdown 
than that observed with positive control C-MYC 
Lipofectamine. 
5 Conclusions 
For siRNA to realize its therapeutic potential, it must 
be functional and freely available within the cytoplasm 
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to interact with the RISC complex. When relying on a 
GSH-based release strategy, this study highlights the 
importance of particle design, in terms of supporting 
ligand densities such as PEG, and intracellular GSH 
levels, which differ between cell types. To achieve 
these aims, a multidisciplinary approach is strongly 
recommended, allowing a feedback loop between cell 
biologists and chemists in order to redesign aspects 
of the NP, with a view to tailoring the particles for 
specific cells and tissues. 
 
Electronic Supplementary Material: Supplementary 
material (GSH intracellular levels in multiple cell 
types) is available in the online version of this article 
at http://dx.doi.org/ 10.1007/s12274-015-0828-5. 
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